Alpha Centric Advisors LLC Viracta Therapeutics, Inc. Transaction History

Alpha Centric Advisors LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$3.32 - $5.69 $298,800 - $512,100	-90,000 Closed	0 $0
Q4 2021 Feb 25, 2022	SELL	$3.37 - $7.91 $8,094 - $18,999	-2,402 Reduced 2.6%	90,000 $329,000
Q1 2021 Mar 09, 2022	BUY	$7.58 - $18.67 $700,407 - $1.73 Million	92,402 New	92,402 $855,000

9.39M

5.9K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $18.4M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.